ArticleInternational journal of molecular sciences2026
Toward Advanced Quantitative Prediction of Missense Variant Effects.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Predicting how missense variants alter protein function is central to resolving the genotype-to-phenotype equation, a task now addressed by numerous computational predictors. The most accurate are increasingly opaque, however, limiting both their mechanistic value and their adoption in the clinic. Here we present QAFIsplit, a redesign of the Quantitative Assessment of Functional Impact framework that models variant effect in two interpretable stages: the mutation tolerance of a position, and the deviation introduced by a specific substitution. Framed as the prediction of a molecular endophenotype, QAFIsplit reaches state-of-the-art quantitative accuracy on independent deep mutational scanning benchmarks, surpassing black-box predictors such as AlphaMissense in most protein domains. Carried into clinical variant classification, it performs on par with established clinical tools without ever being trained on clinical labels, and complements meta-predictors without penalty. In the CAGI 7 community experiment, QAFI-based strategies were submitted blindly to four independent disease-gene challenges, backed by strong pre-submission clinical validation (AUC up to 0.99).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.